A physician in our network was having dinner with a group of entrepreneurs. None of them worked in health care. But one mentioned a former health IT executive who had built a technology platform for hospital operations. The physician, who spent his days inside hospitals and immediately recognized the problem the product was solving, picked up his phone, called me, and said, “You need to look at this.”

That call led to one of the best investments I’ve ever made. And it happened because a physician embedded in a completely unrelated context spotted a health care opportunity that no venture capitalist would have seen.

This is how physician-led deal sourcing actually works. Not through pitch competitions or accelerator demo days. Through the daily lives of over 200 physicians across more than 20 medical specialties, at institutions spanning the country, who are constantly encountering clinical problems, and who have been trained to recognize when someone is building a solution worth investigating.

How the network actually operates

When a potential deal surfaces, whether through a physician LP, a direct referral, or the GP’s own sourcing channels, it enters a process that looks nothing like traditional venture capital diligence.

The first step is routing. I identify which specialists in the network are closest to the clinical problem the company is addressing. If it’s a surgical device, I send materials to surgeons who perform the relevant procedures. If it’s a hospital operations platform, I go to nursing leaders, supply chain executives, and hospital administrators alongside physicians. If it’s a therapeutic targeting a specific disease, I reach out to specialists who treat that condition daily.

The second step is structured feedback. These aren’t casual opinions. I send each reviewer the company’s materials, including product documentation, clinical data, published studies, and patent filings when relevant, along with specific diligence questions. The reviewers assess the product against their lived clinical experience. Does this solve a real problem? Would they use it? Would their colleagues adopt it? What are the barriers to implementation in their specific clinical setting?

The third step is synthesis. The feedback comes back, sometimes within days, and patterns emerge quickly. When five specialists independently flag the same concern about a product, that’s not anecdotal. That’s a clinical consensus that no market research firm could produce.

Three outcomes I’ve seen play out

Over seven years, this process has produced three distinct patterns.

The first is unanimous rejection. I once sent a medical device opportunity to five specialists who would be the product’s primary users. All five independently identified the same problem: The clinical need was overstated, and the existing workflow was entrenched enough that no single-feature device could displace it. We passed in eleven days. The deal source, a prominent tech investor and former CEO of a NASDAQ-listed company, later acknowledged the quality of our clinical diligence. That relationship now generates ongoing deal flow. Saying no with rigor builds more credibility than saying yes without it.

The second is unanimous validation. For a health tech company targeting hospital compliance workflows, I took the product concept to 17 frontline health care professionals. Every one of them validated the need, not politely, but with frustration. They described the manual workarounds they’d built because no good solution existed. That signal, anger at the status quo from the people living inside it, was the strongest buy indicator I could have received. That company now serves multiple health systems.

The third, and most powerful, is when validation turns into personal investment. A drug-device combination being developed at a major research university went to more than 10 specialists in the relevant field. Six of them were so convinced by the science and the unmet clinical need that they committed their own capital as co-investors. They didn’t just validate the opportunity. They put skin in the game. And those same physicians are now part of the product’s future adoption pathway. They’ll be among the first clinicians to use it when it reaches patients.

That last pattern is the one I look for most carefully. When the physicians who review a deal are willing to invest their own money, the clinical conviction is real. No survey, focus group, or consultant report produces that level of signal.

Why this model can’t be replicated by traditional VC

Most venture firms hire analysts with MBAs and consulting backgrounds. They’re smart and disciplined. But they don’t have a cardiologist they can call at 9 p.m. to ask whether a remote monitoring device will change clinical practice. They don’t have OR nurses who can evaluate whether a surgical tool fits existing workflows. They don’t have a chief nursing officer who can explain why a procurement committee will approve one product and reject another.

This network of 200-plus physicians grew organically over years. Every physician joined through a direct referral. No marketing, no recruitment campaign. It grew because physicians trusted other physicians’ judgment, saw the quality of the diligence, and wanted to participate. That trust is the network’s most valuable asset.

What this means for physicians who aren’t investors

You don’t have to write checks to participate in this kind of work. The physician network model creates multiple roles for clinicians who want to contribute their expertise to health care innovation.

Some physicians serve as clinical reviewers, evaluating products against their daily practice and providing structured feedback that shapes investment decisions. Others serve as clinical advisors to portfolio companies, helping startups understand how their product will actually be used in a hospital setting. Others become connectors, introducing startups to health system leaders, clinical trial sites, or potential customers within their professional networks.

Every one of these contributions leverages something physicians have in abundance but rarely get to deploy outside of patient care: deep clinical knowledge applied to health care business decisions.

The health care venture capital industry deploys tens of billions of dollars every year. Most of that capital is allocated without meaningful input from the people who understand health care best. When physicians organize, not as passive investors, but as an active clinical intelligence network, the quality of every investment decision improves. Better capital allocation means better products reaching patients. And better products mean better medicine.

That’s what happens when 200 physicians review a startup together. The investment gets smarter. And so does health care.

Harsha Moole is an internal medicine-trained physician-scientist with more than 100 peer-reviewed publications, including work featured in the New England Journal of Medicine. After years of clinical practice and gastroenterology outcomes research, he made an unconventional transition from the bedside to the boardroom by founding PhysicianEstate, a health care-focused venture capital firm.

Over the past seven years, Dr. Moole has made 22 early-stage health care investments across digital health, medical devices, biotech, and therapeutics. He has also built a network of more than 200 physicians from institutions such as Johns Hopkins and Stanford who help source opportunities and provide clinical diligence before capital is deployed. His core thesis is that physician-scientists with firsthand clinical experience are uniquely positioned to identify health care investments that generalist investors often miss.

His research background is reflected in his publication record on Google Scholar, and he shares professional updates on LinkedIn.